Literature DB >> 21953840

Prevalence of pulmonary hypertension in hereditary spherocytosis.

Shelley E Crary1, Claudio Ramaciotti, George R Buchanan.   

Abstract

Vascular complications, including pulmonary hypertension (PH), have been reported to occur following splenectomy for various disorders,including hereditary spherocytosis (HS). We performed a prospective cross-sectional study of 36 adults with HS (78% with prior splenectomy)utilizing echocardiography to estimate tricuspid regurgitant jet velocity (TRV) as well as measurement of N-terminal pro-B-type natriuretic peptide (NT-proBNP) to screen for PH. No participant with HS hada significantly elevated TRV or NT-proBNP level, despite a median 25-year interval since splenectomy (95% confidence interval for point prevalence 0, 0.097). Although our study was limited by a small sample size, it appears that persons with HS, following splenectomy, appear unlikely to be at significantly increased risk of developing PH to the degree reported for thalassemia and sickle cell disease

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21953840     DOI: 10.1002/ajh.22182

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  11 in total

Review 1.  Abnormalities of the erythrocyte membrane.

Authors:  Patrick G Gallagher
Journal:  Pediatr Clin North Am       Date:  2013-10-15       Impact factor: 3.278

2.  Elevated tricuspid regurgitant jet velocity in subgroups of thalassemia patients: insight into pathophysiology and the effect of splenectomy.

Authors:  Sylvia T Singer; Frans Kuypers; Jeffery Fineman; Ginny Gildengorin; Sandra Larkin; Nancy Sweeters; Howard Rosenfeld; Gregory Kurio; Annie Higa; Michael Jeng; James Huang; Elliott P Vichinsky
Journal:  Ann Hematol       Date:  2014-02-28       Impact factor: 3.673

Review 3.  Pulmonary hypertension associated with chronic hemolytic anemia and other blood disorders.

Authors:  Roberto F Machado; Harrison W Farber
Journal:  Clin Chest Med       Date:  2013-10-17       Impact factor: 2.878

Review 4.  How I treat hypoxia in adults with hemoglobinopathies and hemolytic disorders.

Authors:  Evans M Machogu; Roberto F Machado
Journal:  Blood       Date:  2018-09-11       Impact factor: 22.113

5.  OPSI threat in hematological patients.

Authors:  B Serio; L Pezzullo; V Giudice; R Fontana; S Annunziata; I Ferrara; R Rosamilio; C De Luca; M Rocco; N Montuori; C Selleri
Journal:  Transl Med UniSa       Date:  2013-05-06

Review 6.  Hematological disorders and pulmonary hypertension.

Authors:  Rajamma Mathew; Jing Huang; Joseph M Wu; John T Fallon; Michael H Gewitz
Journal:  World J Cardiol       Date:  2016-12-26

7.  Recommendations regarding splenectomy in hereditary hemolytic anemias.

Authors:  Achille Iolascon; Immacolata Andolfo; Wilma Barcellini; Francesco Corcione; Loïc Garçon; Lucia De Franceschi; Claudio Pignata; Giovanna Graziadei; Dagmar Pospisilova; David C Rees; Mariane de Montalembert; Stefano Rivella; Antonella Gambale; Roberta Russo; Leticia Ribeiro; Jules Vives-Corrons; Patricia Aguilar Martinez; Antonis Kattamis; Beatrice Gulbis; Maria Domenica Cappellini; Irene Roberts; Hannah Tamary
Journal:  Haematologica       Date:  2017-05-26       Impact factor: 9.941

8.  Pulmonary arterial hypertension associated with hereditary spherocytosis and splenectomy in a patient with a mutation in the BMPR2 gene.

Authors:  Adolfo Baloira; María Bastos; Guillermo Pousada; Diana Valverde
Journal:  Clin Case Rep       Date:  2016-06-30

Review 9.  Congenital Hemolytic Anemias: Is There a Role for the Immune System?

Authors:  Anna Zaninoni; Elisa Fermo; Cristina Vercellati; Anna Paola Marcello; Wilma Barcellini; Paola Bianchi
Journal:  Front Immunol       Date:  2020-06-23       Impact factor: 7.561

Review 10.  Therapeutic approaches to limit hemolysis-driven endothelial dysfunction: scavenging free heme to preserve vasculature homeostasis.

Authors:  Francesca Vinchi; Emanuela Tolosano
Journal:  Oxid Med Cell Longev       Date:  2013-05-27       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.